Infectious diseases & vaccines

U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1

This approval offers a new HIV-1 treatment option for children in the U.S. at least 2 years of age, weighing 14 kg – 25 kg and living with HIV

March 20, 2024

Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis

Submission is supported by data from the Phase 3 QUASAR program, which showed a significantly greater percentage of patients with moderately to severely active ulcerative colitis who received TREMFYA® achieved clinical remission at Week 44 compared with placebo

March 11, 2024

Infectious diseases & vaccines

Janssen Enters into Agreement with Sanofi to Advance Potential First-In-Class Vaccine Program

October 3, 2023

Infectious diseases & vaccines

Janssen Takes Further Legal Action to Help End the Distribution of Counterfeit HIV Medicines in the United States

September 6, 2023

Infectious diseases & vaccines

Janssen Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy EDURANT®